First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017) - Schuler, M.; Paz-Ares, L.; Sequist, L.V.; Tan, E.H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, L.; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; et al.